

References

1. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. *Nat Immunol*. 2007;8:913-919.
2. Bermel RA, Fox RJ. The role of MRI in multiple sclerosis diagnosis and management. Medscape Today Web site. Available at: <http://www.medscape.com/viewprogram/6184>. Accessed November 3, 2008.
3. Rudick RA, Lee JC, Simon J, et al. Defining interferon beta response status in multiple sclerosis patients. *Ann Neurol*. 2004;56:548-555.
4. Filippi M, Rocca MA, Arnold DL, et al. EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. *Eur J Neurol*. 2006;13:313-325.
5. Schmierer K, Tozer DJ, Scaravilli F, et al. Quantitative magnetization transfer imaging in postmortem multiple sclerosis brain. *J Magn Reson Imaging*. 2007;26:41-51.
6. Rovaris M, Filippi M. Diffusion tensor MRI in multiple sclerosis. *J Neuroimaging*. 2007;17(suppl 1):27S-30S.
7. Song SK, Sun SW, Ramsbottom MJ, et al. Dysmyelination revealed through MRI as increased radial (but unchanged axial) diffusion of water. *Neuroimage*. 2002;17:1429-1436.
8. Rocca MA, Filippi M. Functional MRI in multiple sclerosis. *J Neuroimaging*. 2007;17(suppl 1):36S-41S.
9. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). *Ann Neurol*. 1996;39:285-294.
10. IFNB Multiple Sclerosis Study Group. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. *Neurology*. 1993;43:655-661.
11. IFNB Multiple Sclerosis Study Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. *Neurology*. 1995;45:1277-1285.
12. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. *Neurology*. 1995;45:1268-1276.

13. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. *Lancet*. 1998;352:1498-1504.
14. Cohen BA, Khan O, Jeffery DR, et al. Identifying and treating patients with suboptimal responses. *Neurology*. 2004;63(12 suppl 6):S33-S40.
15. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. *Neurology*. 2003;61:1528-1532.
16. Rudick RA, Lee JC, Simon J, Fisher E. Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study. *Ann Neurol*. 2006;60:236-242.
17. Rudick RA, Lee JC, Simon J, et al. Defining interferon beta response status in multiple sclerosis patients. *Ann Neurol*. 2004;56:548-555.
18. Hakiki B, Goretti B, Portaccio E, et al. 'Subclinical MS': follow-up of four cases. *Eur J Neurol*. 2008;15:858-861.
19. Weinstock-Guttman B, Ramanathan M. Switching therapy in multiple sclerosis: challenge and potential. *Medscape Neurol Neurosurg*. 2007. Available at: <http://www.medscape.com/viewarticle/563037>. Accessed November 25, 2008.
20. Traboulsee A, Al-Sabbagh A, Bennett R, et al. Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (Evidence of Interferon Dose-response: European North American Comparative Efficacy) study. *BMC Neurol*. 2008;8:11.
21. Namaka M, Pollitt-Smith M, Gupta A, et al. The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosis. *Curr Med Res Opin*. 2006;22:223-239.
22. Rossman HS. Neutralizing antibodies to multiple sclerosis treatments. *J Manag Care Pharm*. 2004;10(3 suppl B):S12-S19.
23. Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology*. 2007;68:977-984.
24. Sørensen PS, Deisenhammer F, Duda P, et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. *Eur J Neurol*. 2005;12:817-827.

25. Limmroth V, Malessa R, Zettl UK, et al. Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis. *Neurol.* 2007;254:67-77.
26. Cook S, Coyle PK, Cross A, et al. Changing therapy in relapsing multiple sclerosis: considerations and recommendations of a task force of the National Multiple Sclerosis Society. Available at: <http://www.nationalmssociety.org/download.aspx?id=129>. Accessed November 20, 2008.
27. Stüve O. The effects of natalizumab on the innate and adaptive immune system in the central nervous system. *J Neurol Sci.* 2008;274:39-41.
28. Stüve O, Bennett JL. Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. *CNS Drug Rev.* 2007;13:79-95.
29. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. *N Engl J Med.* 2006;354:899-910.
30. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. *N Engl J Med.* 2006;354:911-923.
31. Boren EJ, Cheema GS, Naguwa SM, et al. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. *J Autoimmun.* 2008;30:90-98.
32. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. *N Engl J Med.* 2005;353:369-374.
33. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. *N Engl J Med.* 2005;353:375-381.
34. Mitoxantrone [prescribing information]. Rockland, MD: EMD Sorono Inc; 2008.